SCYNEXIS, Inc. Net Income (Loss) Available to Common Stockholders, Basic
SCYNEXIS, Inc. (SCYX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$29.99 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-13.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2017-03-13
- SCYNEXIS, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2015-12-31 was -$8.39M.
- SCYNEXIS, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2015-09-30 was -$8.36M.
- SCYNEXIS, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2015-06-30 was -$9.50M, a 581.84% decline year-over-year.
- SCYNEXIS, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2015-03-31 was -$6.38M.
- SCYNEXIS, Inc. net income (loss) available to common stockholders, basic for fiscal 2016 was -$29.99M.
- SCYNEXIS, Inc. net income (loss) available to common stockholders, basic for fiscal 2015 was -$32.62M.
- SCYNEXIS, Inc. net income (loss) available to common stockholders, basic for fiscal 2014 was -$5.87M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2016-12-31 | -$29.99M 10-K · filed 2017-03-13 | |||
| 2015-12-31 | -$8.39M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | -$16.74M derived: sum of 2 quarters · filed 2017-03-13 | -$26.24M derived: sum of 3 quarters · filed 2017-03-13 | -$32.62M 10-K · filed 2017-03-13 |
| 2015-09-30 | -$8.36M 10-Q · filed 2015-11-13 | -$17.85M derived: sum of 2 quarters · filed 2015-11-13 | -$24.23M 10-Q · filed 2015-11-13 | -$27.31M derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-06-30 | -$9.50M 10-Q · filed 2015-08-19 | -$15.88M 10-Q · filed 2015-08-19 | -$18.96M derived: sum of 3 quarters · filed 2017-03-13 | -$22.76M derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-03-31 | -$6.38M 8-K · filed 2015-10-30 | -$9.46M derived: sum of 2 quarters · filed 2017-03-13 | -$13.26M derived: sum of 3 quarters · filed 2017-03-13 | -$11.29M derived: sum of 4 quarters · filed 2017-03-13 |
| 2014-12-31 | -$3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | -$6.88M derived: sum of 2 quarters · filed 2017-03-13 | -$4.91M derived: sum of 3 quarters · filed 2017-03-13 | -$5.87M 10-K · filed 2017-03-13 |
| 2014-09-30 | -$3.80M 10-Q · filed 2015-11-13 | -$1.83M derived: sum of 2 quarters · filed 2015-11-13 | -$2.79M 10-Q · filed 2015-11-13 | -$41.13M derived: sum of 4 quarters · filed 2015-11-13 |
| 2014-06-30 | $1.97M 10-Q · filed 2015-08-19 | $709.00K 10-Q · filed 2015-08-19 | -$37.33M derived: sum of 3 quarters · filed 2015-10-30 | -$41.29M derived: sum of 4 quarters · filed 2015-10-30 |
| 2014-03-31 | -$1.22M 8-K · filed 2015-10-30 | -$39.30M derived: sum of 2 quarters · filed 2015-10-30 | -$43.26M derived: sum of 3 quarters · filed 2015-10-30 | -$45.96M derived: sum of 4 quarters · filed 2015-10-30 |
| 2013-12-31 | -$38.08M derived: 8-K 12 month − 10-Q 9 month · filed 2015-10-30 | -$42.04M derived: sum of 2 quarters · filed 2015-10-30 | -$44.74M derived: sum of 3 quarters · filed 2015-10-30 | -$46.81M 8-K · filed 2015-10-30 |
| 2013-09-30 | -$3.96M 10-Q · filed 2014-11-13 | -$6.66M derived: sum of 2 quarters · filed 2014-11-13 | -$8.73M 10-Q · filed 2014-11-13 | |
| 2013-06-30 | -$2.70M 10-Q · filed 2014-08-13 | -$4.77M 10-Q · filed 2014-08-13 | ||
| 2013-03-31 | -$2.07M 10-Q/A · filed 2014-07-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |